Serina Therapeutics Launches Enhanced Corporate Communications Platform to Strengthen Engagement with Patients, Clinicians, and Investors
Serina Therapeutics, Inc. (SER)
Company Research
Source: GlobeNewswire
HUNTSVILLE, AL., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today announced the launch of a comprehensive corporate communications platform designed to deliver timely, transparent updates to patients, clinicians, investors, and the broader scientific community. The new initiative expands Serina’s direct channels of communication to provide stakeholders with clear, accessible information on the Company’s programs, regulatory progress, and scientific advances. The platform will feature regular digital updates, educational resources, multimedia content, and expert commentary from company leadership and scientific advisors. “At Serina, we believe leadership in biotechnology requires not only advancing innovative science but also communicating that progress with clarity and transparency,” said Steve Ledger, Chief Executive Offic
Show less
Read more
Impact Snapshot
Event Time:
SER
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SER alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SER alerts
High impacting Serina Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
SER
News
- Serina Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business HighlightsGlobeNewswire
- Serina Therapeutics Provides Regulatory Update on SER-252 ProgramGlobeNewswire
- Serina Therapeutics Draws First $5 Million Funding Tranche to Support Registrational Trial of SER-252 in Parkinson's Disease [Yahoo! Finance]Yahoo! Finance
- Serina Therapeutics Draws First $5 Million Funding Tranche to Support Registrational Trial of SER-252 in Parkinson’s DiseaseGlobeNewswire
- Serina Therapeutics Secures Up to $20 Million to Advance Registrational Trial of SER-252 in Parkinson's Disease [Yahoo! Finance]Yahoo! Finance
SER
Sec Filings
- 12/4/25 - Form 4
- 11/26/25 - Form 4
- 11/25/25 - Form 4
- SER's page on the SEC website